Showing results (151-160 of 226) with videos related to
Sort By:
Pageof 23
The American Journal of Emergency Medicine|September 10, 2010
A simple and useful coma scale for patients with neurologic emergencies: the Emergency Coma ScaleChiaki Takahashi, Hiroshi Okudera, Hideki Origasa, et al.Stroke|March 8, 2018
Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke)Naohisa Hosomi, Kazuo Kitagawa, Yoji Nagai, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|May 4, 2010
Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: a Japanese Multicenter Cooperative RegistryShinichiro Uchiyama, Yoshisato Shibata, Takayuki Hirabayashi, et al.International Journal of Rheumatic Diseases|January 21, 2020
Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritisYoshiya Tanaka, Tatsuya Atsumi, Kazuhiko Yamamoto, et al.Journal of Atherosclerosis and Thrombosis|September 27, 2019
Effect of Statin on Stroke Recurrence Prevention at Different Infarction Locations: A Post Hoc Analysis of The J-STARS StudyTomohisa Nezu, Naohisa Hosomi, Kazuo Kitagawa, et al.World Journal of Diabetes|April 16, 2025
B-type natriuretic peptide efficacy compared to fragmented QRS for diastolic dysfunction screening in patients with type 2 diabetesKunimasa Yagi, Daisuke Chujo, Isao Usui, et al.Heart and Vessels|July 8, 2018
Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND StudyShinichiro Uchiyama, Hirotsugu Atarashi, Hiroshi Inoue, et al.International Journal of Cardiology|August 24, 2023
Effectiveness and safety of reduced-dose rivaroxaban for elderly patients with non-valvular atrial fibrillation: A subanalysis of the EXPAND studyWataru Shimizu, Shinichiro Uchiyama, Hirotsugu Atarashi, et al.Journal of Atherosclerosis and Thrombosis|September 29, 2024
Antiplatelets for Cardiovascular Disease in Non-valvular AF with Rivaroxaban: A Subanalysis of the EXPAND StudyKoichi Kaikita, Shinichiro Uchiyama, Hirotsugu Atarashi, et al.Heart and Vessels|August 4, 2019
Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysisIchiro Sakuma, Shinichiro Uchiyama, Hirotsugu Atarashi, et al.Pageof 23